Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Reviewer Retention Remains Priority In FY 2001 - User Fee Report

This article was originally published in The Tan Sheet

Executive Summary

FDA will implement ideas from employee focus groups in FY 2001 to try to improve the retention rate in its drug review divisions, the agency said in its fiscal 2000 Prescription Drug User Fee Act Financial Report.

You may also be interested in...

CDER deputy director

A candidate has been identified, but announcement has been postponed due to the Bush Administration's hiring freeze, Office of Pharmaceutical Science Acting Director Helen Winkle told NAPM annual meeting attendees in Las Croabas, Puerto Rico Jan. 31. Prospective deputy is not an agency employee, but "he will do a lot for the center in helping to promote the activities that are going on," Winkle said

Hiring Freeze Will Affect FDA Commissioner, ORM Director Appointments

Acting FDA Commissioner Bernard Schwetz, PhD, will continue to make funding the agency's science base a top priority, he stresses in a Jan. 22 email to agency staff.

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts